Dishman Carbogen Amcis Ltd

Dishman Carbogen Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dishman Carbogen Amcis Ltd

₹ 251 1.60%
30 Jun - close price
dishmangroup.com BSE: 540701 NSE: DCAL
About

Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.[1]

Key Points

Business Segments & Revenue Contribution

Website BSE NSE - BE
  • Market Cap ₹ 3,934 Cr.
  • Current Price ₹ 251
  • High / Low ₹ 308 / 155
  • Stock P/E
  • Book Value ₹ 372
  • Dividend Yield 0.00 %
  • ROCE 2.44 %
  • ROE -0.34 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Stock is trading at 0.67 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 5.82% over past five years.
  • Company has a low return on equity of -1.05% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
569 541 614 640 619 723 587 651 655 524 789 682 716
547 452 535 526 567 602 526 610 592 495 642 542 564
Operating Profit 22 88 79 114 51 122 61 41 63 29 147 140 153
OPM % 4% 16% 13% 18% 8% 17% 10% 6% 10% 6% 19% 21% 21%
-8 6 9 4 -39 7 5 6 4 -4 4 8 -4
Interest 16 19 20 22 24 28 27 33 31 32 37 49 42
Depreciation 84 75 80 50 76 70 75 80 85 71 72 72 79
Profit before tax -85 -0 -12 46 -88 29 -36 -66 -49 -78 42 27 28
Tax % -48% -1,437% -18% -3% -19% 42% 13% -10% 42% 0% 21% 83% -56%
-45 4 -10 47 -71 17 -41 -60 -70 -78 33 5 43
EPS in Rs -2.85 0.26 -0.64 3.00 -4.51 1.08 -2.61 -3.80 -4.46 -4.95 2.11 0.30 2.75
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,031 1,714 1,695 2,059 2,044 1,912 2,141 2,413 2,616 2,712
830 1,261 1,249 1,507 1,540 1,638 1,809 2,081 2,329 2,243
Operating Profit 201 452 445 552 503 274 331 332 286 469
OPM % 20% 26% 26% 27% 25% 14% 15% 14% 11% 17%
14 26 46 54 39 16 29 -20 22 4
Interest 56 49 49 57 62 48 57 86 120 159
Depreciation 69 214 211 240 283 308 308 281 311 294
Profit before tax 91 216 231 309 197 -65 -4 -55 -122 19
Tax % 12% 33% 33% 32% 20% 154% -524% -45% 26% 83%
80 145 155 210 159 -165 18 -30 -153 3
EPS in Rs 9.58 13.03 10.10 -10.53 1.15 -1.90 -9.79 0.21
Dividend Payout % 0% 0% 0% 2% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 6%
3 Years: 8%
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 87%
Stock Price CAGR
10 Years: %
5 Years: 15%
3 Years: 29%
1 Year: 43%
Return on Equity
10 Years: %
5 Years: -1%
3 Years: -1%
Last Year: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 16 0.00 32 32 31 31 31 31 31 31
Reserves 863 4,814 5,075 5,347 5,684 5,667 5,518 5,778 5,596 5,800
868 950 1,095 1,042 1,357 1,589 1,830 2,209 2,313 2,389
334 811 967 899 1,121 1,068 1,255 1,421 1,631 1,779
Total Liabilities 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 9,999
1,012 4,852 5,066 5,098 5,678 5,698 5,773 6,188 6,724 7,270
CWIP 307 133 151 175 234 486 780 1,043 646 255
Investments 1 40 196 167 191 172 324 249 102 97
761 1,550 1,757 1,881 2,091 2,000 1,758 1,959 2,098 2,377
Total Assets 2,081 6,574 7,169 7,321 8,193 8,356 8,634 9,439 9,571 9,999

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
203 303 226 282 585 513 355 266 384 375
-231 -107 -297 -169 -442 -380 -619 -494 -230 -192
25 -137 78 -102 -98 -11 130 250 -22 -102
Net Cash Flow -3 59 7 11 46 122 -133 22 132 81

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2011 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 60 61 96 79 103 80 81 89 64 90
Inventory Days 272 473 525 496 462 402 526 568 540 655
Days Payable 172 95 201 176 226 132 158 155 149 168
Cash Conversion Cycle 160 439 419 399 340 350 449 502 455 577
Working Capital Days 49 117 129 135 124 135 115 90 100 103
ROCE % 5% 6% 4% 0% 1% 1% 0% 2%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32% 59.32%
5.85% 6.20% 7.20% 9.34% 8.90% 8.80% 8.60% 8.70% 8.05% 8.18% 8.75% 9.49%
6.63% 4.26% 3.86% 2.55% 3.13% 3.51% 3.68% 2.36% 1.47% 1.22% 1.42% 1.26%
28.19% 30.22% 29.61% 28.79% 28.65% 28.37% 28.39% 29.63% 31.17% 31.29% 30.51% 29.94%
No. of Shareholders 56,98659,65461,17556,58356,22156,27252,33650,65653,68355,28052,82250,757

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls